As part of the strategic realignment of its US business, the company has filed for voluntary liquidation under Chapter 7 of ...

Wockhardt will exit its loss-making US generic business to focus on antibiotics and diabetes care. The company filed for ...

New Delhi, July 12 (UNI) Reserve Bank of India or RBI, the country’s premier central bank, conducted a seven-day auction of Variable Rate Reverse Repo or VRRR. This auction is aimed at absorbing the ...

The company stated that the decision follows years of losses in the US generics segment, with FY25 alone seeing losses of ...

Wockhardt announces its exit from the US generics market, shifting focus to its innovative antibiotic and biologicals ...

By exiting the US generics space, the company aims to redirect capital and executive focus toward two key growth areas: novel ...

Central Florida individuals and businesses that have filed for liquidation under Chapter 7 of the U.S. Bankruptcy Code include: ...

Wockhardt restructures US business, focusing on innovation and exiting generics, filing for voluntary liquidation for ...

Mumbai: Wockhardt has announced a significant strategic realignment of its U.S. business, marking an exit from the generic ...

Wockhardt Ltd on July 11 said it has decided to exit US generic pharmaceutical segment to unlock capital for high-impact ...

Wockhardt says its US generics business has been loss-making for several years, incurring a loss of nearly $8 million in FY25 ...

In Indian currency, Pang’s deal translates to over Rs 1,600 crore, while Bansal’s offer is worth around Rs 800 crore.